Year: 2024

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on November 13, 2024. Posted in Earnings Releases And Operating Results.

– OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025– – Commercial Planning in Progress for 2025 Launch – – Late Breaker Poster Presentation on OLC at ASN Kidney Week – – Successful Completion of UNI-494 Phase 1 Trial – LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2024, and provided a business update. “We are pleased with the tremendous progress we have made over the last several months highlighted by the acceptance of our New Drug Application for oxylanthanum carbonate (OLC) which may result in the potential approval of our first...

Vaccines Market is Expected to Develop at a Moderate 3.70% CAGR through 2031 | SkyQuest Technology

Written by Customer Service on November 13, 2024. Posted in Mergers And Acquisitions.

Westford,USA, Nov. 13, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Vaccines market will attain a value of USD 99.85 billion by 2031, with a CAGR of 3.70% over the forecast period (2024-2031). Surging prevalence of chronic diseases and increasing launch of new vaccination programs around the world are projected to bolster the demand for vaccines in the future. Rising investments in vaccine R&D and growing emphasis on preventive healthcare around the world are also projected to promote sales of vaccines over the coming years. Download a detailed overview:https://www.skyquestt.com/sample-request/vaccines-market Browse in-depth TOC on “Vaccines Market”Pages – 212 Tables – 147 Figures – 71Vaccines market Overview:Report Coverage DetailsMarket Revenue in 2023 $ 74.66 billionEstimated...

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Written by Customer Service on November 13, 2024. Posted in Earnings Releases And Operating Results.

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive license agreement with ALK-Abelló to commercialize neffy® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royaltiesWell-capitalized with $349.6 million in cash, cash equivalents and short-term investments on a pro forma basis, supporting an operating runway of at least three yearsCompany to host conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers...

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on November 13, 2024. Posted in Earnings Releases And Operating Results.

Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appeal Strengthened balance sheet by raising approximately $100 million in additional capitalMORRISVILLE, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the third quarter ended September 30, 2024. The company will host a webcast at 8:30 a.m. ET on November 13, 2024, to discuss...

Hut 8 Reports Third Quarter 2024 Results

Written by Customer Service on November 13, 2024. Posted in Earnings Releases And Operating Results.

Strategic initiatives drive revenue growth, balance sheet strength, and competitive position across AI compute and Bitcoin mining Earnings Release HighlightsRevenue of $43.7 million, net income of $0.9 million, and Adjusted EBITDA of $5.6 million Energy cost per MWh of $28.83, a 33% decrease from $42.73 in the prior year period Mined 234 Bitcoin at a weighted average revenue per Bitcoin mined of $61,025, compared to a cost to mine of $31,482 9,106 Bitcoin held in reserve with a market value of $576.5 million and total cash of $72.9 million as of September 30, 2024MIAMI, Nov. 13, 2024 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), a leading, vertically integrated operator of large-scale energy infrastructure and one of North America’s largest Bitcoin miners, today announced its financial results...

Hyperscale Data Announces a Special Dividend of 10% Series E Cumulative Redeemable Perpetual Preferred Stock

Written by Customer Service on November 13, 2024. Posted in Dividend Reports And Estimates.

All Common and Series C Convertible Preferred Stockholders to Receive Planned Dividend LAS VEGAS, Nov. 13, 2024 (GLOBE NEWSWIRE) — Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data,” or the “Company”), previously announced on November 6, 2024 that it plans to issue a special one-time dividend (the “Distribution”) of a newly designated 10% Series E Cumulative Redeemable Perpetual Preferred Stock (the “Series E Preferred Stock”) to all common stockholders and holders of the Series C Convertible Preferred on an as-converted basis. The Company hereby announces that the record date for the Distribution has been set for November 26, 2024. Stockholders who own the Company’s stock at the close of trading on that date will be eligible to receive the shares of Series E Preferred Stock. Further,...

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Written by Customer Service on November 13, 2024. Posted in Mergers And Acquisitions.

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform and therapeutic products for unmet medical needs in oncology and autoimmune diseases and (ii) Entero’s gastrointestinal product pipeline for treating unmet metabolic and rare genetic diseases; The NIC platform technology is invented by and originated from Svetomir N. Markovic, M.D., Ph.D. of Mayo Clinic and is exclusively licensed by Journey with worldwide rights to sublicense; The NIC technology employs the cutting edge cancer drug – nanoparticle albumin-bound (“NAB”) paclitaxel Abraxane – as a therapeutic backbone, combining with (i) on-demand tumor-targeting, tumor-suppressing and/or immune checkpoint inhibitor therapeutic antibody and (ii)...

Dental Practice Management Software Market to Grow at USD 2.90 Billion by 2031

Written by Customer Service on November 13, 2024. Posted in Mergers And Acquisitions.

Westford,USA, Nov. 13, 2024 (GLOBE NEWSWIRE) — Dental Practice Management Software Market size was valued at USD 1.38 billion in 2022 and is poised to grow from USD 1.50 billion in 2023 to USD 2.90 billion by 2031, growing at a CAGR of 8.6% in the forecast period (2024-2031). The market is anticipated to grow significantly, owing to the rising dental visits, increasing focus & awareness about oral health, and the rapid technological advancement. The Health Information Technology for Economic and Clinical Health encouraged the growth while providing the use of health information technology in the United States. Moreover, the adoption of healthcare IT solutions, especially by the speciality clinics like oral practices is expected to increase insurance coverage. Hence, the above reasons are expected to result in the increased...

American Shared Hospital Services Reports Third Quarter 2024 Financial Results

Written by Customer Service on November 13, 2024. Posted in Earnings Releases And Operating Results.

– Revenue increases 36.3% period over period – Conference Call on November 13th at 1:00 pm ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent HighlightsTotal revenue in the third quarter was $6,999,000, an increase of 36.3% from the comparable period in 2023 bolstered by the completion of our acquisition in May 2024 (the “RI Acquisition”) of 60% of the equity interest of two entities in Rhode Island (the “RI Companies”) that operate three Rhode Island radiation therapy facilities...

Osisko Development Reports Third Quarter 2024 Results

Written by Customer Service on November 13, 2024. Posted in Earnings Releases And Operating Results.

(All monetary references are expressed in Canadian dollars, unless otherwise indicated) MONTREAL, Nov. 13, 2024 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) reports its financial and operating results for the three months ended September 30, 2024 (“Q3 2024“). Q3 2024 HIGHLIGHTS Operating, Financial and Corporate Updates:As at September 30, 2024, the Company had approximately $40.8 million in cash and cash equivalents. An amount of approximately $67.7 million (US$50.0 million) was fully drawn as at September 30, 2024 under the delayed draw term loan with National Bank of Canada maturing October 31, 2025.Following the completion of the non-brokered private placement on October 14, 2024 (see Subsequent to Q3 2024) and pursuant to...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals